Reports indicate that Eli Lilly's high valuation is prompting rivals like AstraZeneca, Merck, and Bristol-Myers Squibb to consider strategic tie-ups or acquisitions.
1 report, 1 independent
Updated Aug 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Reports indicate that Eli Lilly's high valuation is prompting rivals like AstraZeneca, Merck, and Bristol-Myers Squibb to consider strategic tie-ups or acquisitions.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company
-
Bristol-Myers Squibb
American pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- Nvidia, Eli Lilly, and Booking Holdings are high-growth stocks attracting investor attention, with Eli Lilly being specifically compared to Booking Holdings' stock split.
- Soutrik Banerjee is currently employed as a consultant at Eli Lilly and Company.
- Langone's portfolio ranking favors Eli Lilly over Home Depot.